CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

James Pekarsky Joins Gelteq as Chief Financial Officer

James Pekarsky Joins Gelteq as Chief...

BioStem Technologies Announces the Approval of Q Code for VENDAJE from CMS

BioStem Technologies Announces the...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

James Pekarsky Joins Gelteq as Chief Financial Officer

James Pekarsky Joins Gelteq as Chief...

BioStem Technologies Announces the Approval of Q Code for VENDAJE from CMS

BioStem Technologies Announces the...

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Life Sciences Review Life Sciences Review | Monday, January 24, 2022
Tweet

TCR² Therapeutics selects Rosemary Harrison as Chief Business and Strategy Officer.


FREMONT, CA: “We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR² as she has proven throughout her career an ability to work closely with multiple commercial functions to identify and execute clear strategic priorities," states Garry Menzel, Ph.D., President and Chief Executive Officer of TCR² Therapeutics. "We look forward to her immediate operational impact as 2022 is a year full of milestones in which our lead program gavo-cel will enter a Phase 2 clinical trial, TC-510 will enter a Phase 1 clinical trial and several other programs; provide opportunities for strategic dialogue.” TCR² Therapeutics Inc., a clinical-stage cell therapy company developing novel T cell therapies for patients with solid tumors, has appointed Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer. In this role, she will support various activities, including commercial strategy, operational planning, corporate partnerships, and long-term growth opportunities.


Dr. Harrison brings over two decades of global experience in strategic planning, portfolio management, and business development to TCR². Before joining the company, she served as Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics, where she was instrumental in the company's November 2021 acquisition by Pfizer for $2.22 billion. Dr. Harrison has held positions in strategy and research at RA Capital Management and as Head of Rare Diseases at Imbria Pharmaceuticals. She formerly worked as the Head of Portfolio Management and Strategy Planning at the Novartis Institutes for Biomedical Research and as a consultant at Bain & Company. She advised on corporate strategic and operational initiatives. Dr. Harrison graduated from The University of Queensland with a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. in Biotechnology.


“TCR2s first-in-class T cell platform is highly differentiated by leveraging the full TCR complex, independent of HLA and has already demonstrated encouraging clinical data in treatment-refractory solid tumors,” states Dr. Harrison. “I am thrilled to be joining TCR2 during such an important period and look forward to working with the outstanding team to focus priorities and support a clear execution plan.”


Weekly Brief

loading
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing
Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/rosemary-harrison-joins-tcr-therapeutics-as-chief-business-and-strategy-officer-nwid-701.html